U.S. markets closed
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • Dow 30

    33,781.48
    +183.56 (+0.55%)
     
  • Nasdaq

    11,082.00
    +123.45 (+1.13%)
     
  • Russell 2000

    1,818.29
    +11.39 (+0.63%)
     
  • Crude Oil

    71.79
    +0.33 (+0.46%)
     
  • Gold

    1,801.30
    +3.30 (+0.18%)
     
  • Silver

    23.27
    +0.35 (+1.54%)
     
  • EUR/USD

    1.0560
    +0.0046 (+0.43%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • GBP/USD

    1.2239
    +0.0034 (+0.28%)
     
  • USD/JPY

    136.6330
    +0.1090 (+0.08%)
     
  • BTC-USD

    17,221.09
    +372.49 (+2.21%)
     
  • CMC Crypto 200

    405.01
    +10.32 (+2.62%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands

  • Novartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patients in clinical trials, and building capability and talent, among other actions, will enable Novartis to achieve this objective.

  • Novartis' aspiration is "to improve competitive positioning and organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.

  • In April, Novartis announced integrating its pharmaceuticals and oncology units into the Innovative Medicines business to simplify its structure, targeting savings of at least $1 billion by 2024. The transformation nears completion.

  • Also See: Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya.

  • It stated that Novartis is also aiming to be a top-three player in China, a key growth market for the next decade, while maintaining leading positions in Germany and Japan.

  • Novartis announced a strategy based on eight big drug brands as the pharma giant reshapes itself following the decision to spin off its underperforming generics unit, Sandoz.

  • During the investor event, Novartis said the currently in-market brands - Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto, and Scemblix - each held multibillion-dollar peak sales potential.

  • Novartis also said it would focus in the future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors, and hematology medicine.

  • The company confirmed its previous financial targets, "we will continue to deliver improved financials with +4% sales CAGR through 2027 and a core operating income margin ~40%+ in the mid-long term," it added.

  • Price Action: NVS shares are down 1.32% at $76.52 during the premarket session on the last check Thursday.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.